Anti-AAV Immunity: A Translational Constraint for Reprogramming Trials
Pre-existing anti-AAV antibodies constrain in vivo reprogramming programs that rely on AAV delivery; which programs actually need this screening is the key open question.
Some adults carry neutralizing or capsid-binding antibodies against AAV — the adeno-associated virus used for gene delivery. They need to be screened out before dosing: pre-existing immunity raises the risk of immune-mediated complications.
This directly constrains in vivo tissue reprogramming. The approach: transiently express Yamanaka or related factors (OSK) in adult tissues to reverse cellular age marks and restore function, without pushing cells into full dedifferentiation. When delivery relies on AAV, pre-existing immunity in a portion of candidates shrinks the participant pool before the trial even starts.
Our assessment: a serious barrier between lab and clinic. Confidence is high. Screening for anti-AAV immunity before enrollment makes trial design tighter and feasibility estimates more reliable.
Open questions:
— Which in vivo reprogramming programs actually use AAV vectors, and which have chosen other delivery methods?
— Has any reprogramming trial built this screening into its inclusion criteria?
The answers will determine where this screening matters first.
This edge connects clinical-trial infrastructure (anti-AAV immunity measurement) to in vivo reprogramming feasibility — a mechanistically strong dependency that reprogramming coverage consistently ignores, and one where the system's data is thin enough to warrant an honest route assessment with concrete next steps.